Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24945821 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL23216537 | 0.77 | DRD2 (0.46) | SLC6A2SLC6A4SLC6A3HPGDTSHR | |
| SCHEMBL29768482 | 0.77 | DRD2 (0.46) | SLC6A2SLC6A4SLC6A3HPGDTSHR | |
| SCHEMBL23216263 | 0.76 | FTO (0.39) | SLC6A2SLC6A4SLC6A3HPGDTSHR | |
| SCHEMBL3982753 | 0.73 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3DRD2TACR1 | |
| SCHEMBL29768379 | 0.72 | OPRM1 (0.33) | SLC6A2SLC6A4SLC6A3HPGDTSHR | |
| SCHEMBL23216631 | 0.72 | OPRM1 (0.33) | SLC6A2SLC6A4SLC6A3HPGDTSHR | |
| SCHEMBL14314489 | 0.69 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL8820689 | 0.68 | SLC6A4 (0.41) | SLC6A2SLC6A4SLC6A3DRD2TACR1 | |
| SCHEMBL188283 | 0.67 | SLC6A4 (0.60) | SLC6A2SLC6A4SLC6A3DRD2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-4041407-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114746151-A | Aryl heterocyclic compounds as Kv1.3 potassium Shaker channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021071802-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071802-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNA3, KCNH2, KCNJ2 | SLC6A2 990/4885SLC6A4 1195/4885SLC6A3 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.